ARCHIVES

“Sloppy” Searle Studies Described By FDA At Kennedy Hearing; Rauscher “Outraged”

This article is from The Cancer Letter archive.

Vol. 02 No. 04 | January 23, 1976

Download PDF Visit The Full Archive

Related Articles

Phase III Trial Would Give Clearer Picture Of C225 Role.

February 15, 2002

Centers Subcommittee Kills Guidelines Proposal, Suggest Formula Ceiling On Core Grants

January 6, 1978

BRCA Status Can Guide Ovarian Cancer Treatment

April 25, 2008

FDA Approves Folotyn For Peripheral T-Cell Lymphoma

September 25, 2009

White House Proposes NCI Budget Cut Of $40 Million or FY2007; NIH Budget Flat. Cuts And Earmarks Threaten To Derail 2015 Goal, NCI Director Says; “We Are In Difficult Times.”

February 10, 2006

In Brief: Griesemer Returns To NIEHS to Head Toxicology Research & Testing; Robert Burnight Dies at 69

August 12, 1988